Rechallenging patients with ICIs may not be beneficial in advanced RCC, but Tivozanib monotherapy shows promise as an ...

The regulation and remodeling of the tumor microenvironment (TME) are closely associated with how cancers typically progress ...

FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to ...

Vyloy is the first CLDN 18.2-targeted treatment to reach the US market alongside Roche's Ventana CLDN18 RxDx Assay for identifying eligible patients.

Adding immunotherapy to platinum-gemcitabine chemotherapy can improve outcomes in patients with advanced urothelial carcinoma, but that may depend on the platinum agent used, data suggest.

It may soon be possible to determine which patients with a type of liver cancer called hepatocellular carcinoma would benefit ...

Astellas Pharma Inc. (ALPMY, ALPMY) said that the U.S. Food and Drug Administration has approved VYLOY (zolbetuximab-clzb) in ...

What’s more, AM-101 improved radiation treatment, slowing down the growth of NSCLC subcutaneous xenograft tumors in mice, by ...

The company is preparing for the Phase 3 study start in the first quarter of 2025BRISBANE, Calif., Oct. 10, 2024 (GLOBE ...

Combined company will operate as TuHURA Biosciences, Inc. and advance pipeline of novel technologies to overcome resistance to cancer ...

Exelixis is advancing its pipeline with zanalintinib and XB010, exploring new avenues in oncology beyond its cabozantinib ...

According to a preclinical study conducted by Weill Cornell Medicine researchers, it may soon be feasible to detect whether ...